Libido
Increase · moderate
Melanocortin receptor activation
Literature evidence
Compound library
Vivy evidence dossier
PT-141 (Bremelanotide)
Also indexed as Bremelanotide, PT-141, Melanotan II analog
T1Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life2 hr
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
Systolic blood pressure
Increase · small
Transient pressor effects
Literature evidence
Diastolic blood pressure
Increase · small
Transient pressor effects
Literature evidence
Keep in view
Safety discussion points
PT-141 (bremelanotide) is a melanocortin agonist approved by FDA for hypoactive sexual desire disorder (HSDD) in women. Not FDA-approved for other uses.
Keep the reference close
Track PT-141 (Bremelanotide) in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.